Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H24FN3O4.ClH.H2O |
Molecular Weight | 455.908 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(OC)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O
InChI
InChIKey=SKZIMSDWAIZNDD-WJMOHVQJSA-N
InChI=1S/C21H24FN3O4.ClH.H2O/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H;1H2/t11-,16+;;/m0../s1
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361
Moxifloxacin is a synthetic antibacterial agent developed by Bayer AG (initially called BAY 12-8039) for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Moxifloxacin is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avalon for oral treatment. In most countries, the drug is also available in the parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11600361
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4088 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16337789 |
800.0 nM [IC50] | ||
Target ID: CHEMBL4165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20516287 |
9200.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | AVELOX Approved UseINDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date1999 |
|||
Curative | AVELOX Approved UseINDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date1999 |
|||
Curative | AVELOX Approved UseINDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date1999 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 mg/L |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.2 mg/L |
400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.9 mg/L |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.5 mg/L |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
443.07 ng/ml Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01296191 |
1 drop 4 times / day multiple, ocular dose: 1 drop route of administration: ocular experiment type: multiple co-administered: |
MOXIFLOXACIN aqueous humor | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36.1 mg × h/L |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
38 mg × h/L |
400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
39.3 mg × h/L |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
48 mg × h/L |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.55 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
14.8 h |
400 mg 1 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
11.8 h |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.7 h |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
60% |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MOXIFLOXACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral Higher than recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: Page: p.5 |
healthy, 30±7 n = 7 Health Status: healthy Age Group: 30±7 Sex: M Population Size: 7 Sources: Page: p.5 |
|
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: Page: p.2062 |
healthy, 33.6 n = 8 Health Status: healthy Age Group: 33.6 Sex: M Population Size: 8 Sources: Page: p.2062 |
|
400 mg 1 times / day multiple, intravenous Recommended Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash Sources: Page: p.8.9 |
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (>0.3) Sources: Page: p.8.9Diarrhea (>0.3) Dizziness (>0.3) Vomiting (>0.3) |
800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: Page: p.7 |
unhealthy, 57.8 n = 5 Health Status: unhealthy Condition: Chronic bronchitis Age Group: 57.8 Sex: M+F Population Size: 5 Sources: Page: p.7 |
|
400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: Page: p.1863 |
unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: Page: p.1863 |
Disc. AE: Erythema, QT interval prolonged... AEs leading to discontinuation/dose reduction: Erythema (0.37%) Sources: Page: p.1863QT interval prolonged (1%) Angioedema (serious, 0.37%) |
400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Disc. AE: Tendinitis, Tendon rupture... AEs leading to discontinuation/dose reduction: Tendinitis Sources: Page: p.1Tendon rupture Peripheral neuropathy Central nervous system disorder NOS Myasthenia gravis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rash | Disc. AE | 400 mg 1 times / day multiple, intravenous Recommended Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Diarrhea | >0.3 Disc. AE |
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Dizziness | >0.3 Disc. AE |
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Nausea | >0.3 Disc. AE |
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Vomiting | >0.3 Disc. AE |
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.8.9 |
unhealthy, 50 Health Status: unhealthy Condition: Bacterial infections Age Group: 50 Sex: M+F Sources: Page: p.8.9 |
Erythema | 0.37% Disc. AE |
400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: Page: p.1863 |
unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: Page: p.1863 |
QT interval prolonged | 1% Disc. AE |
400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: Page: p.1863 |
unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: Page: p.1863 |
Angioedema | serious, 0.37% Disc. AE |
400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Co-administed with:: Linezolid, IV(600 mg q12h) Sources: Page: p.1863 |
unhealthy, 59.6 n = 273 Health Status: unhealthy Condition: Community-acquired bacterial pneumonia Age Group: 59.6 Sex: M+F Population Size: 273 Sources: Page: p.1863 |
Central nervous system disorder NOS | Disc. AE | 400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Myasthenia gravis | Disc. AE | 400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Peripheral neuropathy | Disc. AE | 400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Tendinitis | Disc. AE | 400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
Tendon rupture | Disc. AE | 400 mg 1 times / day multiple, oral|intravenous Recommended Dose: 400 mg, 1 times / day Route: oral|intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. | 2000 Jan |
|
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. | 2000 May |
|
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. | 2000 Oct |
|
Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. | 2001 |
|
Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. | 2001 |
|
Treatment of Staphylococcus aureus endocarditis using moxifloxacin. | 2001 Aug |
|
Acute community-acquired pneumonia: current diagnosis and treatment. | 2001 Jan |
|
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. | 2001 Jan |
|
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. | 2001 Jul |
|
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. | 2001 Jun |
|
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. | 2001 Jun |
|
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. | 2001 Mar |
|
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. | 2001 Mar |
|
Moxifloxacin: clinical efficacy and safety. | 2001 Mar 1 |
|
Clinical perspectives on new antimicrobials: focus on fluoroquinolones. | 2001 Mar 15 |
|
Evaluation of the clinical microbiology profile of moxifloxacin. | 2001 Mar 15 |
|
Profile of moxifloxacin drug interactions. | 2001 Mar 15 |
|
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. | 2001 Mar 15 |
|
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity. | 2001 Mar 15 |
|
Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. | 2001 Mar-Apr |
|
Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae. | 2001 Mar-Apr |
|
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. | 2001 May |
|
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. | 2001 Nov |
|
Pharmacokinetics and pharmacodynamics of fluoroquinolones. | 2001 Oct |
|
In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. | 2001 Sep |
|
The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. | 2001 Sep |
Sample Use Guides
The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection (5--21 days).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9687105
Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. Moxifloxacin was active against all tested staphylococci with MICs of 0.063–2 mg/L.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1049063
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY | |||
|
DBSALT002560
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY | |||
|
192927-63-2
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY | |||
|
9890250
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY | |||
|
B8956S8609
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY | |||
|
B8956S8609
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY | |||
|
1926505
Created by
admin on Fri Dec 15 16:39:44 GMT 2023 , Edited by admin on Fri Dec 15 16:39:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD